Today: 15.Apr.2021
(EANM, European Association of Nuclear Medicine) Austria, Europe - Prostate cancer radium 223
Rate this item
(0 votes)

European Association of Nuclear Medicine: At an advanced stage prostate cancer frequently leads to bone metastases which may result in pain, fractures, and disability and are associated with a poor prognosis. Recently a major breakthrough has been achieved which is about to improve the patients’ situation, as Prof. Markus Luster, expert of the European Association of Nuclear Medicine (EANM), points out: “Radium-223- dichloride is the first bone-targeted drug that not only alleviates symptoms but also prolongs the life expectancy of these patients.

Read 997 times Last modified on Sunday, 03 May 2020 05:30